Polynovo (ASX:PNV) share price rises despite widening losses

The Polynovo Ltd (ASX:PNV) share price is rising slightly today, despite the company reporting a loss for the first half of FY2021.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Polynovo Ltd (ASX: PNV) shares are swinging around today after the company released its earnings report for the first half of the 2021 financial year (1H21) before market open this morning. At the time of writing, the Polynovo share price has risen 0.83% to $2.43 after climbing as high as $2.47 earlier in the day.

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

What did Polynovo report this morning?

Polynovo is an ASX health care company that specialises in treatments for burn injuries and other skin maladies.

The Polynovo share price is staying afloat today after the biotech reported that revenues for 1H21 came in at $12.8 million, up 25.3% over the $10.2 million from the prior corresponding period (1H20). Gross margins for product sales rose 3.9% as well.

However, that was offset by expenses increasing 32.6% from $11.2 million in 1H20 to $13 million in 1H21. A large component of this increase came from increased staff headcount.

That rise in expenses helped push earnings before interest, tax, depreciation and amortisation (EBITDA) to a loss of $2.9 million, up 46.2% from the previous loss of $1 million. Earnings before interest and tax (EBIT) losses also rose 41%, going from a loss of $2.4 million in 1H20 to a loss of $3.3 million in 1H21.

That resulted in Polynovo delivering a net profit after tax loss of $3.54 million, up 46.3% from the $2.42 million loss of 1H20.

Overall, the company posted an underlying loss of $0.87 million for 1H21, down 40.2% from its loss of $1.45 million in 1H20. No dividend was announced, in case you were wondering.

Polynovo has blamed the coronavirus pandemic on "lumpy" revenues for the period, citing "reduced access and reduced elective surgery in all regions".

Even so, the company has pointed to a 31.2% rise in sales of its flagship NovoSorb product as a bright spot over the period. It also highlighted the fact it managed to sign 22 additional customers in the United States, which brings the total new accounts opened for the 2020 calendar year to 109. That's an 89% rise over the 2019 calendar year.

About the Polynovo share price

Although the Polynovo share price is having a decent day today, the company has had a rough start to the year. Polynovo shares remain down 37.15% year to date, and down more than 14% over the past 12 months. In saying that, Polynovo shares are still up more than 1,170% since August 2017.

On the current Poynovo share price, the company has a market capitalisation of around $1.61 billion.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another rough one for investors this Tuesday.

Read more »

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Morgans says hold BHP shares and buy this ASX 200 stock      

Let's see what the broker is saying about these stocks this week.

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

3 ASX 200 shares just upgraded to strong buy — here's what the brokers are saying

Do any of these ASX 200 stocks appeal to you?

Read more »

A disappointed man slumps in his chair and holds his head while playing an online game.
52-Week Lows

These 4 ASX 200 shares have slumped to fresh 52-week lows: Buy, sell or hold?

Should investors buy in the dip or sit on the sidelines?

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Beach Energy, Domino's, Origin Energy, and Pantoro Gold shares are dropping today

Why are these shares under pressure? Let's find out.

Read more »

A woman wearing a hard hat holds two sparking wires together as energy surges between them.
Share Market News

Origin Energy shares slump 10% this week: Buy, sell or hold?

The ASX energy company has hit some headwinds. How much longer can they continue?

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »